6UGX
Crystal structure of the Fc fragment of PF06438179/GP1111 an infliximab biosimilar in a primative orthorhombic crystal form, Lot A
Experimental procedure
| Experimental method | SINGLE WAVELENGTH | 
| Source type | SYNCHROTRON | 
| Source details | APS BEAMLINE 21-ID-F | 
| Synchrotron site | APS | 
| Beamline | 21-ID-F | 
| Temperature [K] | 100 | 
| Detector technology | CCD | 
| Collection date | 2015-10-22 | 
| Detector | RAYONIX MX-225 | 
| Wavelength(s) | 0.97872 | 
| Spacegroup name | P 21 21 21 | 
| Unit cell lengths | 49.400, 74.610, 149.090 | 
| Unit cell angles | 90.00, 90.00, 90.00 | 
Refinement procedure
| Resolution | 50.000 - 2.100 | 
| R-factor | 0.2011 | 
| Rwork | 0.198 | 
| R-free | 0.25630 | 
| Structure solution method | MOLECULAR REPLACEMENT | 
| Starting model (for MR) | 4cdh | 
| RMSD bond length | 0.008 | 
| RMSD bond angle | 0.838 | 
| Data reduction software | XDS | 
| Data scaling software | XSCALE | 
| Phasing software | PHASER | 
| Refinement software | PHENIX | 
Data quality characteristics
| Overall | Inner shell | Outer shell | |
| Low resolution limit [Å] | 50.000 | 50.000 | 2.150 | 
| High resolution limit [Å] | 2.100 | 9.390 | 2.100 | 
| Rmerge | 0.094 | 0.033 | 0.499 | 
| Rmeas | 0.103 | 0.038 | 0.545 | 
| Number of reflections | 32975 | 420 | 2430 | 
| <I/σ(I)> | 13.68 | 29.21 | 3.75 | 
| Completeness [%] | 99.8 | 95.9 | 100 | 
| Redundancy | 6.031 | 4.971 | 6.134 | 
| CC(1/2) | 0.997 | 0.996 | 0.885 | 
Crystallization Conditions
| crystal ID | method | pH | temperature | details | 
| 1 | VAPOR DIFFUSION, SITTING DROP | 289 | 10 mg/mL protein with 200 mM potassium nitrate, 20% PEG3350, cryoprotectant: 20% ethylene glycol, puckID sxt1-6 | 











